Clinical Trial Update: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating the combination of bortezomib and panobinostat in relapsed or refractory peripheral T-cell lymphomas and NK/T-cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-negative
• Anaplastic Large Cell Lymphoma Alk-positive
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Hepatosplenic T-cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• Bortezomib (bortezomib)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Singapore General Hospital | Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: COMPLETED